EUVIMEDEUVIMED entdecken
Open Access

Osteoporosis medication use over time in the United States and Canada

Kaleen N Hayes, Andrew R Zullo, Sarah D Berry, Arman Oganisian, Sulbh Aggarwal, Michael Adegboye, Suzanne M Cadarette

Osteoporosis International · 2025

DOI: 10.1007/s00198-025-07484-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Osteoporosis International, 2025. Verfasst von Kaleen N Hayes und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Services, Policy, and Practice and Center for Gerontology and Healthcare Research, Brown University School of Public Health, 121…. Hauptthemen laut MEDLINE: Bone Density Conservation Agents, Osteoporosis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, National Institute on Aging.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Over 12 years in the US and 26 years in Ontario, Canada, we found major differences in osteoporosis medications used. In both countries, osteoporosis medication initiation has not returned to pre-2008 levels; however, denosumab use is increasing. Future work should determine whether targeted screening or undertreatment drives these trends. PURPOSE: Concerns about adverse events caused a rapid decline in osteoporosis medication use globally between 2008 and 2012. Trends in use in recent years have not been described. We aimed to describe and compare trends over time in the initiation and overall use of osteoporosis medications among older adults in the US and Ontario, Canada. METHODS: We conducted a serial cross-sectional study leveraging two data sources: healthcare administrative data for all older adult residents of Ontario, Canada (ON) and Medicare claims and enrollment data for a 20% random sample of beneficiaries (US). We included community-dwelling older adults aged ≥ 66 years at their first dispensing of an osteoporosis medication between 05/01/1996-12/31/2022 in ON and 01/01/2008-12/31/2020 in the US. We described and compared the number of incident and prevalent users of osteoporosis medications annually. RESULTS: We identified 771,025 (average age = 75.2 years; 78% female) individuals in ON and 424,995 (average age = 75.3 years; 85% female) in the US initiating osteoporosis medications. In the US, alendronate and denosumab were the most common therapies, while in ON, risedronate and denosumab were most common. New use of osteoporosis medications dropped more between 2008 and 2011 in the US versus ON (58% vs. 29% relative decrease). Initiation of osteoporosis medications did not rebound to pre-2008 levels. CONCLUSION: New use of osteoporosis medications remains below pre-2008 levels, and differs between the US and Canada. Future research should aim to understand drivers of decreased use, like changes in the screening strategy used for initial treatment or persisting concerns about adverse effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bone Density Conservation AgentsOsteoporosisHumansAgedUnited StatesFemaleCross-Sectional StudiesMaleAged, 80 and overDrug UtilizationMedicareOntarioPractice Patterns, Physicians'Denosumab

Stichwörter der Autor:innen

Aged patientsBisphosphonatesBone density conservation agentsDenosumabOsteoporosisZoledronic acid

Substanzen

Bone Density Conservation AgentsDenosumab

Autor:innen und Institutionen

  • Department of Health Services, Policy, and Practice and Center for Gerontology and Healthcare Research, Brown University School of Public Health, 121 South Main Street, Providence, Rhode Island, USA. Kaley_hayes@brown.e…
  • Department of Epidemiology, Brown University School of Public Health, Providence, RI, USA. Kaley_hayes@brown.edu.
  • Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada. Kaley_hayes@brown.edu.
  • Department of Health Services, Policy, and Practice and Center for Gerontology and Healthcare Research, Brown University School of Public Health, 121 South Main Street, Providence, Rhode Island, USA.
  • Department of Epidemiology, Brown University School of Public Health, Providence, RI, USA.
  • Hinda and Arthur Marcus Institute for Aging Research, Hebrew Seniorlife and Harvard Medical School, Boston, MA, USA.

Förderung

  • NIA NIH HHS
  • National Institute on Aging

Zitieren

APA

Hayes, K. N., Zullo, A. R., Berry, S. D., Oganisian, A., Aggarwal, S., Adegboye, M., & Cadarette, S. M. (2025). Osteoporosis medication use over time in the United States and Canada. Osteoporosis International. https://doi.org/10.1007/s00198-025-07484-3

Vancouver

Hayes KN, Zullo AR, Berry SD, Oganisian A, Aggarwal S, Adegboye M, et al. Osteoporosis medication use over time in the United States and Canada. Osteoporosis International. 2025. doi:10.1007/s00198-025-07484-3

BibTeX
@article{Hayes2025,
  author = {Hayes, Kaleen N and Zullo, Andrew R and Berry, Sarah D and Oganisian, Arman and Aggarwal, Sulbh and Adegboye, Michael and Cadarette, Suzanne M},
  title = {Osteoporosis medication use over time in the United States and Canada},
  journal = {Osteoporosis International},
  year = {2025},
  doi = {10.1007/s00198-025-07484-3}
}
Kostenlos starten →